CALIBER is a research platform that links electronic health records from primary care, coded hospital records on diagnoses and operations, social deprivation information and cause-specific mortality data in England for roughly ~10 million individuals. CALIBER enables researchers to recreate the longitudinal pathway of patients through care pathways and study disease onset and progression.
More information: CALIBER Data Resource Profile
BigData@Heart is a five-year project of the Innovative Medicines Initiative (IMI), a EU public-private consortium consisting of patient networks, learned societies, SMEs, pharmaceutical companies and academia. BigData@Heart's ultimate goal is to develop a Big Data-driven translational research platform of unparalleled scale and phenotypic resolution in order to deliver clinically relevant disease phenotypes, scalable insights from real-world evidence and insights driving drug development and personalised medicine through advanced analytics.
More information: Project homepage.
NIHR Health Informatics Collaborative
The Health Informatics Collaborative brings together five of the country's leading NIHR Biomedical Research Centres to make NHS clinical data more readily available to researchers, industry and the NHS community. Working in close collaboration with UCLH, our lab is developing scalable data integration pipelines for acute coronary syndrome data.
More information: NIHR Health Informatics Collaborative
Administrative Data Research Centre - England
Part of the ESRC-funded Administrative Data Research Network, ADRC England helps researchers get access to linked administrative data in secure settings for social and economic research. Our lab is leading the Bloomsbury e-Infrastructure efforts by providing a secure facility for researchers.
More information: Administrative Data Research Network
The UK Biobank is a large prospective biobanked cohort of 500,000 middled-aged adults with extensive genomic, baseline and electronic health record data participants. Our lab is leading the efforts of
creating and validating acute coronary syndrome phenotypes and undertaking a series of phenome-wide association studies (PheWAS) by exploiting the rich clinical information found in health records.
More information: UK Biobank
The Intellectual Disability and Mental Htalth: Assessing Genomic Impact on Neurodevelopment (IMAGINE ID) study seeks to increase our understadning of children and young people with intellectual disability that has a genetic cause. Our lab is leading the health informatics workstream of the study with the aim of creating a legacy database integrating genomic, clinical and baseline data for research.
More information: IMAGINE ID
A team of researchers from UCL and the University of Cambridge led by Prof. Sarah Tabrizi, Director of the Huntington's Disease Centre, UCL Institute of Neurology, have been granted a prestigious Wellcome Trust Collaborative Award in one of the largest investments in Huntington's Disease ever given by a public funding body in the UK.
The 5-year, 3.4 million pound investment will support research to help our understanding of disease mechanisms in HD and, importantly, their response to treatment.
More information: TREAT HD
HERMES is an international collaboration to investigate the genetic architecture of heart failure. The consortium comprises 42 population-based studies and clinical trials across Europe and North America and includes over 30,000 heart failure cases and over 200,000 controls. The Consortium's aim is to generate insights into the causal pathways leading to heart failure to inform new therapeutic approaches.
More information: HERMES
GENIUS-CHD is an international consortium of studies of patients with coronary heart disease (either stable disease or acute coronary syndromes) who have had blood or tissue samples stored for analysis and have then been prospectively followed for subsequent events such as death or myocardial infarction. Many of these studies have been created by investigators seeking to identify bio-markers of risk or genetic variations that lead to these groups of patients succumbing to these adverse events.
More information: GENIUS-CHD